Data of a large group of patients younger than 18 years treated according to study AML-Berlin-Frankfurt- Munster (BFM) 98 (n = 454), including their cytogenetics, were analyzed. The favorable outcome in the subgroups of patients with t(8;21), inv(16), and t( 15; 17), with an overall survival of 91% (SE,4%), 92% (SE,6%), and 87% (SE,5%), respectively, was confirmed.
Within this group, the 5-year probability of event-free survival (pEFS) of all 17 children with t( 8; 21) and additional aberrations apart from del(9q) or -X/-Y was 100%. As expected, the cytogenetic finding of a complex karyotype (n = 35; pEFS, 33%; SE, 8%) or a monosomy 7 (n = 12; pEFS, 17%; SE, 11%) was associated with a poor outcome.